Dean Capital Management Sells 2,751 Shares of Encompass Health Co. (NYSE:EHC)

Dean Capital Management cut its holdings in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 11.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 22,197 shares of the company's stock after selling 2,751 shares during the period. Dean Capital Management's holdings in Encompass Health were worth $2,050,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB raised its holdings in Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after purchasing an additional 137 shares in the last quarter. Colonial Trust Co SC purchased a new position in shares of Encompass Health during the fourth quarter valued at about $29,000. Transce3nd LLC bought a new position in Encompass Health in the fourth quarter worth about $40,000. CBIZ Investment Advisory Services LLC lifted its holdings in Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after buying an additional 127 shares during the period. Finally, Tompkins Financial Corp purchased a new position in shares of Encompass Health during the 4th quarter worth approximately $46,000. Hedge funds and other institutional investors own 97.25% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EHC. Truist Financial restated a "buy" rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. KeyCorp boosted their target price on shares of Encompass Health from $120.00 to $122.00 and gave the company an "overweight" rating in a report on Friday, April 25th. UBS Group lifted their price target on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a research report on Monday, April 28th. William Blair restated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Finally, StockNews.com lowered shares of Encompass Health from a "buy" rating to a "hold" rating in a report on Saturday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $120.86.

Insider Activity

In other news, EVP John Patrick Darby sold 10,000 shares of the stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the transaction, the executive vice president now directly owns 79,710 shares of the company's stock, valued at $9,149,910.90. This represents a 11.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. The trade was a 6.79 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company's stock.

Encompass Health Trading Up 0.6 %

Shares of NYSE EHC opened at $117.02 on Wednesday. The company has a market cap of $11.78 billion, a PE ratio of 26.24, a P/E/G ratio of 2.31 and a beta of 0.91. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The firm's 50 day moving average price is $102.40 and its 200-day moving average price is $99.52. Encompass Health Co. has a 52-week low of $82.74 and a 52-week high of $117.98.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, beating the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period last year, the business posted $1.12 EPS. The company's revenue was up 10.6% compared to the same quarter last year. On average, equities research analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend is Tuesday, July 1st. Encompass Health's dividend payout ratio is currently 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

Want to see what other hedge funds are holding EHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Encompass Health Co. (NYSE:EHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.